Meeting at the CIIE | Gluetacs Highlights at the 7th China International Import Expo

ON：2024-11-6 TAGS：GLUETACS THERAPEUTICS

The 7th China International Import Expo (CIIE) grandly opened in Shanghai on November 5th, with new and old friends from around the globe gathering in this vibrant city to attend the annual international trade event. Among all the previous editions, the Shanghai Trading Group, in collaboration with Bank of China, has hosted multiple special project promotion events. This year, the number of projects brought by the Shanghai Trading Group are the most significant to date, with total project scale expected to exceed 15.5 billion yuan.

On November 6th, Gluetacs Therapeutics, as the only innovative drug development company, was invited to participate in the Shanghai Trading Group’s special project promotion event at the 7th CIIE.

Dr. Ren Chaowei, Head of Translational Medicine at Gluetacs, reported at the conference on the incubation process of Gluetacs as a startup, the current competitive landscape of targeted therapies, and the scientific foundation and potential future of the development of protein degrader small molecule drugs. Gluetacs was established based on the foundational scientific research of its two founders, Professor Yang Xiaobao and Jiang Biao, with the support of technology transfer and transformation from ShanghaiTech University and the promotion of capital. The company currently has five molecular glue degraders in the pipeline, among which GT919 and GT929 have entered Phase I clinical studies. GT919 has completed dose escalation, with an average PFS of 6 months for responsive relapsed/refractory multiple myeloma patients, who are still undergoing treatment. The preliminary therapeutic effect has met expectations. Next year, GT919 is planned to conduct clinical trials in combination with CD38 monoclonal antibodies or BCMA/CD3 bispecific antibodies, looking forward to benefiting more multiple myeloma patients in the future. GT818 and GT898 are two bifunctional degraders targeting advanced solid tumors and autoimmune diseases respectively, with plans to submit new drug clinical trial IND applications in the first half of next year.

In addition, Gluetacs has filed over 100 patent applications in the field of molecular glue and bifunctional degraders, in which the development of molecular glue is currently advancing to a new stage. Based on the molecular glue platform built by Gluetacs, we have discovered multiple molecular glue candidates targeting new undruggable targets, which can be used for a broader range of indications, thereby achieving differentiated competitive advantages in the biopharmaceutical market.

Gluetacs looks forward to collaborating and communicating with various types of companies on its self-developed protein degraders, exploring new models of cooperation, and hopes to share the drug development philosophy of protein degraders with China and the world.

Warm Reminder: The promotion conference will be broadcasted online at 14:00 on November 8th. 

Viewing Method: Scan the QR code above to watch the live stream